In what some are calling a boost for the pharmaceutical industry, the New Jersey Supreme Court dismissed hundreds of lawsuits claiming a Roche (RHHBY) drug caused a serious side effect because the company had not properly warned about potential harm. And in doing so, the court reaffirmed a state product liability law that drug makers rely on to defend themselves, but has caused disagreement in lower courts.

At the center of the litigation was the Accutane acne medication, which was alleged in more than 500 lawsuits to have caused inflammatory bowel disease. Roche withdrew the drug nearly a decade ago as generic versions began entering the market, although the company has been dogged by lawsuits claiming the pill was responsible for various maladies, including Crohn’s disease and depression.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy